EP4750460A2 - Feste darreichungsform eines kleinmoleküligen antiviralen wirkstoffes und verwendungen davon - Google Patents

Feste darreichungsform eines kleinmoleküligen antiviralen wirkstoffes und verwendungen davon

Info

Publication number
EP4750460A2
EP4750460A2 EP24846315.0A EP24846315A EP4750460A2 EP 4750460 A2 EP4750460 A2 EP 4750460A2 EP 24846315 A EP24846315 A EP 24846315A EP 4750460 A2 EP4750460 A2 EP 4750460A2
Authority
EP
European Patent Office
Prior art keywords
days
oral dosage
dosage form
form according
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24846315.0A
Other languages
English (en)
French (fr)
Inventor
Joshua L. GROU
Madeline HALOTA
Tycho HEIMBACH
Prapti KAFLE
Rachel Elizabeth KING
Michael Lowinger
Melanie MAROTA
Robert Frederick Meyer
Thomas Morrow
Christopher NEU
Grace A. Okoh
Sanjaykumar Patel
Abraham B. Woldu
Di Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Merck Sharp & Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme LLC filed Critical Merck Sharp & Dohme LLC
Publication of EP4750460A2 publication Critical patent/EP4750460A2/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Saccharide Compounds (AREA)
EP24846315.0A 2023-07-27 2024-07-22 Feste darreichungsform eines kleinmoleküligen antiviralen wirkstoffes und verwendungen davon Pending EP4750460A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363515965P 2023-07-27 2023-07-27
PCT/US2024/038937 WO2025024346A2 (en) 2023-07-27 2024-07-22 Solid dosage form of a small molecule antiviral and uses thereof

Publications (1)

Publication Number Publication Date
EP4750460A2 true EP4750460A2 (de) 2026-06-03

Family

ID=94375754

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24846315.0A Pending EP4750460A2 (de) 2023-07-27 2024-07-22 Feste darreichungsform eines kleinmoleküligen antiviralen wirkstoffes und verwendungen davon

Country Status (7)

Country Link
EP (1) EP4750460A2 (de)
JP (1) JP2026526869A (de)
KR (1) KR20260043113A (de)
CN (1) CN121889150A (de)
AU (1) AU2024300571A1 (de)
MX (1) MX2026000998A (de)
WO (1) WO2025024346A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121337759A (zh) * 2025-11-26 2026-01-16 杭州善礼生物医药科技有限公司 一种磷酸奥司他韦直服颗粒及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9809616B2 (en) * 2012-10-29 2017-11-07 Emory University Pyrimidine nucleosides and their monophosphate prodrugs for the treatment of viral infections and cancer
WO2022262845A1 (en) * 2021-06-18 2022-12-22 Suzhou Spring-Sea Bio-Pharmaceuticals Co., Ltd. Ester derivatives of n4-hydroxycytidine and use thereof
CN114306254B (zh) * 2021-11-30 2023-11-03 南京正济医药研究有限公司 一种Molnupiravir口服固体制剂及其制备方法

Also Published As

Publication number Publication date
WO2025024346A3 (en) 2025-04-10
JP2026526869A (ja) 2026-08-10
MX2026000998A (es) 2026-03-02
CN121889150A (zh) 2026-04-17
WO2025024346A2 (en) 2025-01-30
KR20260043113A (ko) 2026-03-31
AU2024300571A1 (en) 2026-01-29

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260227

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR